Cantor Fitzgerald Reaffirms “Buy” Rating for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals (NASDAQ:AQXP)‘s stock had its “buy” rating reiterated by analysts at Cantor Fitzgerald in a research note issued on Sunday, February 11th. They presently have a $28.00 target price on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 91.52% from the company’s previous close.

The analysts wrote, “R&D day provided contemporary thoughts about IC/BPS and how rosiptor could address an unmet need. We attended an R&D day hosted by AQXP in NYC on Friday, Feb. 9 (presentation here). The company included Dr. Phillip Hanno (Clinical Prof, Stanford U.) on the program to provide a KOL viewpoint of interstitial cystitis/bladder pain syndrome (IC/BPS) and the treatment of it.””

A number of other research analysts have also weighed in on AQXP. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 price target on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Canaccord Genuity reaffirmed a “buy” rating and issued a $22.00 price target on shares of Aquinox Pharmaceuticals in a research note on Tuesday, November 21st. Zacks Investment Research raised shares of Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Tuesday, January 9th. BidaskClub raised shares of Aquinox Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, February 5th. Finally, Guggenheim started coverage on shares of Aquinox Pharmaceuticals in a research note on Thursday, February 8th. They issued a “buy” rating and a $26.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $22.80.

Aquinox Pharmaceuticals (AQXP) opened at $14.62 on Friday. Aquinox Pharmaceuticals has a one year low of $10.02 and a one year high of $18.56.

Hedge funds and other institutional investors have recently bought and sold shares of the company. University of Notre Dame DU Lac raised its holdings in shares of Aquinox Pharmaceuticals by 11.1% in the third quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock valued at $2,700,000 after purchasing an additional 19,066 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after purchasing an additional 17,455 shares during the last quarter. Sphera Funds Management LTD. raised its holdings in shares of Aquinox Pharmaceuticals by 21.7% in the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock valued at $1,072,000 after purchasing an additional 13,450 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after purchasing an additional 2,691 shares during the last quarter. Finally, Investment Centers of America Inc. acquired a new stake in shares of Aquinox Pharmaceuticals in the third quarter valued at approximately $175,000. Institutional investors own 95.93% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://weekherald.com/2018/02/20/cantor-fitzgerald-reiterates-buy-rating-for-aquinox-pharmaceuticals-aqxp.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply